Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update

Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 43,480,000 shares, an increase of 22.8% from the March 15th total of 35,400,000 shares. Based on an average daily volume of 8,220,000 shares, the short-interest ratio is currently 5.3 days.

Ocugen Price Performance

Shares of Ocugen stock traded down $0.12 on Monday, hitting $1.59. The company had a trading volume of 6,878,346 shares, compared to its average volume of 8,232,991. The business has a 50-day simple moving average of $1.16 and a 200-day simple moving average of $0.70. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.08 and a quick ratio of 5.08. The company has a market cap of $407.84 million, a PE ratio of -4.82 and a beta of 3.51. Ocugen has a 52 week low of $0.35 and a 52 week high of $2.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OCGN. WINTON GROUP Ltd acquired a new stake in Ocugen during the first quarter valued at approximately $25,000. Belpointe Asset Management LLC lifted its stake in Ocugen by 11,550.5% during the first quarter. Belpointe Asset Management LLC now owns 34,835 shares of the company's stock valued at $30,000 after purchasing an additional 34,536 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in Ocugen during the second quarter valued at approximately $32,000. Schonfeld Strategic Advisors LLC acquired a new stake in Ocugen during the second quarter valued at approximately $32,000. Finally, Lazard Asset Management LLC lifted its position in shares of Ocugen by 123.9% in the 2nd quarter. Lazard Asset Management LLC now owns 61,432 shares of the company's stock valued at $32,000 after acquiring an additional 33,991 shares in the last quarter. 10.27% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Ocugen in a research report on Wednesday, April 3rd.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.